Search

Your search keyword '"Salerno, M.P."' showing total 21 results
Start Over Author "Salerno, M.P."
21 results on '"Salerno, M.P."'

3. Urinary infections in renal transplant

Author

Romagnoli, J., Favi, E., Salerno, M.P., Citterio, F., Romagnoli, J., Favi, E., Salerno, M.P., and Citterio, F.

Abstract

No abstract, non disponibile

Published
2018

5. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience

Author

Favi, E., primary, Santangelo, R., additional, Iesari, S., additional, Morandi, M., additional, Marcovecchio, G.E., additional, Trecarichi, E.M., additional, Salerno, M.P., additional, Ferraresso, M., additional, Citterio, F., additional, and Romagnoli, J., additional

Published
2017
Full Text
View/download PDF

8. Expanding the Living Donor Pool “Second Act”: Laparoscopic Donor Nephrectomy and ABO-Incompatible Kidney Transplantation Improve Donor Recruitment

Author

Romagnoli, J., primary, Salerno, M.P., additional, Mamode, N., additional, Calia, R., additional, Spagnoletti, G., additional, Bianchi, V., additional, Maresca, M., additional, Piccirillo, N., additional, Putzulu, R., additional, Piselli, P., additional, Cola, E., additional, Zini, G., additional, and Citterio, F., additional

Published
2015
Full Text
View/download PDF

10. Do Patients Who Participate in a Clinic Experimental Protocol Have the Same Probability of Success From That Who Were Not Selected or Refused To Participate? Outcome Surveillance, Safety, and Bioethical Considerations in Kidney Transplant Clinical Research

Author

Pedroso, J.A., primary, Salerno, M.P., additional, Spagnoletti, G., additional, Pietroni, V., additional, Toscano, A., additional, Calia, R., additional, Favi, E., additional, Bianchi, V., additional, Romagnoli, J., additional, and Citterio, F., additional

Published
2014
Full Text
View/download PDF

21. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Author

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, and Mensa FJ

Subjects
Adult, Aged, Aged, 80 and over, Aminoisobutyric Acids, Antiviral Agents adverse effects, Benzimidazoles adverse effects, Cyclopropanes, Drug Combinations, Female, Genotype, Hepacivirus isolation & purification, Hepatitis C, Chronic complications, Humans, Lactams, Macrocyclic, Leucine analogs & derivatives, Male, Middle Aged, Proline analogs & derivatives, Pyrrolidines, Quinoxalines adverse effects, RNA, Viral blood, Sulfonamides adverse effects, Viral Load, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Quinoxalines therapeutic use, Renal Insufficiency, Chronic complications, Sulfonamides therapeutic use
Abstract

Background: Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease. Patients with chronic kidney disease who also have HCV infection are at higher risk for progression to end-stage renal disease than those who have chronic kidney disease without HCV infection. Patients with both HCV infection and advanced chronic kidney disease have limited treatment options., Methods: We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both. Patients had stage 4 or 5 chronic kidney disease and either had received no previous treatment for HCV infection or had received previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medications. The primary end point was a sustained virologic response 12 weeks after the end of treatment., Results: Among the 104 patients enrolled in the trial, 52% had genotype 1 infection, 16% had genotype 2 infection, 11% had genotype 3 infection, 19% had genotype 4 infection, and 2% had genotype 5 or 6 infection. The sustained virologic response rate was 98% (102 of 104 patients; 95% confidence interval, 95 to 100). No patients had virologic failure during treatment, and no patients had a virologic relapse after the end of treatment. Adverse events that were reported in at least 10% of the patients were pruritus, fatigue, and nausea. Serious adverse events were reported in 24% of the patients. Four patients discontinued the trial treatment prematurely because of adverse events; three of these patients had a sustained virologic response., Conclusions: Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection. (Funded by AbbVie; ClinicalTrials.gov number, NCT02651194 .).

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results